论文部分内容阅读
目的探讨左旋咪唑治疗及预防儿童咳嗽变异性哮喘的疗效。方法对49例咳嗽变异性哮喘(cough v,ariantasthm a,CVA)患儿,按照就诊的先后顺序随机分成治疗组25例和对照组24例。对照组接受一般治疗:口服博利康尼和扑尔敏,至咳嗽症状消失后停药,然后随访6个月观察复发情况。治疗组在对照组治疗的基础上加用左旋咪唑口服,至咳嗽症状消失后停用博利康尼及扑尔敏,但仍继续服用左旋咪唑,总疗程达3个月后停药,结束后随访6个月观察复发情况。结果治疗组达到咳嗽缓解所需要的时间(T)与对照组相比无明显差异,但其复发率较对照组明显降低。结论左旋咪唑对于预防咳嗽变异性哮喘的复发疗效显著,副作用少,依从性好。
Objective To investigate the efficacy and safety of levamisole in the treatment of children with cough variant asthma. Methods A total of 49 children with cough v (ariantasthm a, CVA) were randomly divided into treatment group (n = 25) and control group (n = 24) according to the order of treatment. The control group received general treatment: oral carbonic acid and chlorpheniramine, until the cough disappeared after symptoms disappeared, and then followed up for 6 months to observe the recurrence. The treatment group was treated with oral levamisole on the basis of the treatment of the control group. After the symptoms of cough disappeared, the use of levamisole and chlorpheniramine was discontinued. However, levamisole was continued and the treatment was stopped after 3 months. 6 months to observe the recurrence. Results The time (T) in the treatment group to achieve cough relief was not significantly different from that in the control group, but the recurrence rate was significantly lower than that in the control group. Conclusion Levamisole is effective in preventing recurrence of cough variant asthma with few side effects and good compliance.